,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2020', 'fs': 'May 2020', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZFU02AP'}, 'Id': 'a0POZ00000EZFU02AP', 'Event_Date__c': '2020-05-25', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'May 2020', 'Status_History__c': 'a132P000000BwVDQA0'}, 'change': None}]",May 2020,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2020', 'fs': 'Jul 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZFU12AP'}, 'Id': 'a0POZ00000EZFU12AP', 'Event_Date__c': '2020-07-10', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jul 2020', 'Status_History__c': 'a132P000000BwVIQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2020', 'fs': 'Sep 2020', 'change': None}, 'Event_Description': {'s': 'Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 16 October 2020', 'fs': 'Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 16 October 2020', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZFU22AP'}, 'Id': 'a0POZ00000EZFU22AP', 'Event_Date__c': '2020-09-21', 'Event_Description__c': 'Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 16 October 2020', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Sep 2020', 'Status_History__c': 'a132P000000CBZUQA4'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2020', 'fs': 'Sep 2020', 'change': None}, 'Event_Description': {'s': 'Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 16 October 2020', 'fs': 'Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 16 October 2020', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZFU32AP'}, 'Id': 'a0POZ00000EZFU32AP', 'Event_Date__c': '2020-09-22', 'Event_Description__c': 'Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 16 October 2020', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Sep 2020', 'Status_History__c': 'a132P000000CBnDQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that lenvatinib be listed for the treatment of radioactive iodine-refractory differentiated thyroid cancer with a <b>high priority</b> within the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p><b style=""font-size: 9pt;"">Lenvatinib</b></p><p><b style=""font-size: 9pt;"">INITIAL APPLICATION</b><span style=""font-size: 9pt;""> – (thyroid cancer) Applications only from a relevant specialist or any other medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1 \xa0\xa0\xa0\xa0The patient has locally advanced or metastatic differentiated thyroid cancer; and</span></p><p><span style=""font-size: 9pt;"">2 \xa0\xa0\xa0\xa0The patient has radiologically determined progressive disease; and</span></p><p><span style=""font-size: 9pt;"">3 \xa0\xa0\xa0\xa0The patient must be radioactive iodine (RAI) refractory, defined as:</span></p><p><span style=""font-size: 9pt;"">3.1\xa0\xa0A lesion without iodine uptake in a RAI scan; or</span></p><p><span style=""font-size: 9pt;"">3.2 \xa0\xa0Receiving cumulative RAI &gt;600 mCi; or</span></p><p><span style=""font-size: 9pt;"">3.3 \xa0\xa0Experiencing progression after a RAI treatment within 12 months; or</span></p><p><span style=""font-size: 9pt;"">3.4\xa0\xa0Experiencing progression after two RAI treatments administered within 12 months of each other; and</span></p><p><span style=""font-size: 9pt;"">4 \xa0\xa0\xa0\xa0\xa0The patient must have thyroid stimulating hormone (TSH) adequately repressed; and</span></p><p><span style=""font-size: 9pt;"">5 \xa0\xa0\xa0\xa0\xa0The patient must not be a candidate for radiotherapy with curative intent; and </span></p><p><span style=""font-size: 9pt;"">6 \xa0\xa0\xa0\xa0\xa0Surgery is inappropriate; and</span></p><p><span style=""font-size: 9pt;"">7 \xa0\xa0\xa0\xa0\xa0The patient must have a ECOG performance status of 0-1.</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p><b style=""font-size: 9pt;"">RENEWAL</b><span style=""font-size: 9pt;""> – (thyroid cancer) Applications only from a relevant specialist or any other medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1 \xa0\xa0\xa0No evidence of disease progression; and</span></p><p><span style=""font-size: 9pt;"">2 \xa0\xa0\xa0The treatment remains appropriate and the patient is benefiting from treatment.</span></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>In making this recommendation, the Subcommittee considered the high clinical need of patients with radioactive iodine-refractory differentiated thyroid cancer, the disproportionate rate of thyroid cancer in Māori and Pacific peoples, and the moderate strength, good quality evidence of the benefit of lenvatinib in this patient population.</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that lenvatinib be listed for the treatment of radioactive iodine-refractory differentiated thyroid cancer with a <b>high priority</b> within the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p><b style=""font-size: 9pt;"">Lenvatinib</b></p><p><b style=""font-size: 9pt;"">INITIAL APPLICATION</b><span style=""font-size: 9pt;""> – (thyroid cancer) Applications only from a relevant specialist or any other medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1 \xa0\xa0\xa0\xa0The patient has locally advanced or metastatic differentiated thyroid cancer; and</span></p><p><span style=""font-size: 9pt;"">2 \xa0\xa0\xa0\xa0The patient has radiologically determined progressive disease; and</span></p><p><span style=""font-size: 9pt;"">3 \xa0\xa0\xa0\xa0The patient must be radioactive iodine (RAI) refractory, defined as:</span></p><p><span style=""font-size: 9pt;"">3.1\xa0\xa0A lesion without iodine uptake in a RAI scan; or</span></p><p><span style=""font-size: 9pt;"">3.2 \xa0\xa0Receiving cumulative RAI &gt;600 mCi; or</span></p><p><span style=""font-size: 9pt;"">3.3 \xa0\xa0Experiencing progression after a RAI treatment within 12 months; or</span></p><p><span style=""font-size: 9pt;"">3.4\xa0\xa0Experiencing progression after two RAI treatments administered within 12 months of each other; and</span></p><p><span style=""font-size: 9pt;"">4 \xa0\xa0\xa0\xa0\xa0The patient must have thyroid stimulating hormone (TSH) adequately repressed; and</span></p><p><span style=""font-size: 9pt;"">5 \xa0\xa0\xa0\xa0\xa0The patient must not be a candidate for radiotherapy with curative intent; and </span></p><p><span style=""font-size: 9pt;"">6 \xa0\xa0\xa0\xa0\xa0Surgery is inappropriate; and</span></p><p><span style=""font-size: 9pt;"">7 \xa0\xa0\xa0\xa0\xa0The patient must have a ECOG performance status of 0-1.</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p><b style=""font-size: 9pt;"">RENEWAL</b><span style=""font-size: 9pt;""> – (thyroid cancer) Applications only from a relevant specialist or any other medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1 \xa0\xa0\xa0No evidence of disease progression; and</span></p><p><span style=""font-size: 9pt;"">2 \xa0\xa0\xa0The treatment remains appropriate and the patient is benefiting from treatment.</span></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>In making this recommendation, the Subcommittee considered the high clinical need of patients with radioactive iodine-refractory differentiated thyroid cancer, the disproportionate rate of thyroid cancer in Māori and Pacific peoples, and the moderate strength, good quality evidence of the benefit of lenvatinib in this patient population.</p>', 'change': None}, 'Published_Discussion': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that 95% of thyroid cancer is differentiated, of which approximately 5 to 10% of patients will develop metastatic disease, and 60 to 70% of these patients 5-10% patients will become radioiodine refractory (<a href=""https://www.karger.com/Article/Fulltext/502229"" target=""_blank"" style=""font-size: 12pt;""><b>Fugazzola et al. Eur Thyroid J. 2019;8:227–45</b></a>). </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that patients with thyroid cancer in New Zealand are relatively young, with approximately 75% of patients aged 25-64 years (<a href=""https://www.health.govt.nz/system/files/documents/publications/new-cancer-registrations-2017-dec19_0.xlsx"" target=""_blank"" style=""font-size: 12pt;""><b>New Zealand Cancer Registry. 2017</b></a>). The Subcommittee noted that females have a higher rate of thyroid cancer of 8.3 per 100,000, compared with 4.0 per 100,000 for males<b> </b>(<a href=""https://www.health.govt.nz/system/files/documents/publications/new-cancer-registrations-2017-dec19_0.xlsx"" target=""_blank"" style=""font-size: 12pt;""><b>New Zealand Cancer Registry. 2017</b></a>). </p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that Māori are disproportionately affected by thyroid cancer, with an age-standardised rate of thyroid cancer registration in 2015 of 8.6 per 100,000 for Māori compared with 5.4 per 100,000 for non-Māori, while mortality from thyroid cancer was 1.7 for Māori compared with 0.3 per 100,000 for non-Māori (Ministry of Health. 2020, <i>provided to supplier</i>). The Subcommittee also noted that Pacific people have previously been reported to have a higher age-standardised rate of thyroid cancer compared with European/other New Zealanders; standardised rate ratio 1.27 for Pacific males compared with European/other males (95% confidence interval (CI): 0.74-2.18) and 3.58 (2.87-4.47) for Pacific females compared with European/other females (<a href=""https://www.otago.ac.nz/wellington/otago036828.pdf"" target=""_blank"" style=""font-size: 12pt;""><b>Meredith et al. Canc Caus Contr. 2012;23:1173-84</b></a>). </p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>\xa0The Subcommittee noted the results of the randomised (2:1), double-blind, placebo-controlled phase III SELECT trial after the primary data cut-off in November 2013 (<a href=""https://pubmed.ncbi.nlm.nih.gov/25671254/"" target=""_blank"" style=""font-size: 12pt;""><b>Schlumberger et al. N Engl J Med. 2015;372:621-30</b></a>). The Subcommittee noted that 10-15% of trial participants had poorly differentiated thyroid cancer and that this patient group was not included as part of this application. The Subcommittee noted that the median progression-free survival was 18.3 months in the lenvatinib group compared with 3.6 months in placebo; hazard ratio (HR) for progression or death 0.21 (95% CI: 0.14-0.31; P&lt;0.001). The Subcommittee noted that the response rate was 64.8% in the lenvatinib group compared with 1.5% in the placebo group, odds ratio 28.9 (95% CI: 12.5-66.9; P&lt;0.001). </p><p>1.4.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that 95.6% of patients originally assigned to placebo crossed over to lenvatinib in the subsequent optional open-label extension phase of the trial. The Subcommittee noted that the crude overall survival was not statistically significant, and considered that this was likely due to the large amount of cross over; however, when adjusted to correct for potential cross-over effects (resampling with a bootstrapping method), the reported crossover-corrected hazard ratio was 0.62 (95% CI: 0.40- to 1.00, P=0.051; <a href=""https://www.nejm.org/doi/suppl/10.1056/NEJMoa1406470/suppl_file/nejmoa1406470_appendix.pdf"" target=""_blank"" style=""font-size: 12pt;""><b>Figure S4 in the Supplementary Appendix to Schlumberger et al. 2015</b></a>). </p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that NICE guidance published in <a href=""https://www.nice.org.uk/guidance/ta535/resources/lenvatinib-and-sorafenib-for-treating-differentiated-thyroid-cancer-after-radioactive-iodine-pdf-82606902620101"" target=""_blank"" style=""font-size: 12pt;""><b>August 2018</b></a><span style=""font-size: 12pt; font-family: Arial, sans-serif;""> regarding lenvatinib (and sorafenib) for treating differentiated thyroid cancer after radioactive iodine had reported that</span><span style=""background-color: rgb(250, 250, 251); color: black;""> “in SELECT, median overall survival for lenvatinib was 41.6\xa0months compared with 34.5\xa0</span><span style=""background-color: rgb(250, 250, 251); color: rgb(14, 14, 14);"">months for placebo. After correcting for crossover, there was a statistically significant overall survival benefit for lenvatinib compared with placebo (RPSFT-adjusted HR 0.54, 95% bootstrapping CI 0.36 to 0.80)”, where RPSFT referred to the rank preserving structural failure time method. The Subcommittee noted that the supplier application had stated this was based on analysis of an August 2015 data cut-off </span>with median OS of 41.6 months for lenvatinib versus 19.1 months for placebo. The Subcommittee considered the statistical methodology to be appropriate and that the statistically adjusted crossover-corrected results appeared credible.\xa0</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the RECIST v1.1 response rate according to RECIST v1.1 in the lenvatinib group, from an updated analysis with data cut-off in September 2016, was 64.8% compared with 1.5% in the placebo group (odds ratio 28.87, 95% CI: 12.46-66.86, P&lt;0.001). The Subcommittee also noted that the median duration of response for all lenvatinib responders was 30 months, indicating lenvatinib responders having prolonged, durable and clinically meaningful responses (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958278/"" target=""_blank"" style=""font-size: 12pt;""><b>Gianoukakis et al. Endocr Relat Cancer. 2018;25:699-704</b></a>).</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that this single randomised controlled trial represented good quality evidence of moderate strength. </p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered the Special Authority proposed by the supplier was overall appropriate. The Subcommittee considered that the WHO performance status should be amended to the Eastern Cooperative Oncology Group (ECOG) performance status, noting that while the two measurements are very similar in practice, New Zealand clinicians are more familiar ECOG, and that this would also maintain consistency with other oncology Special Authority criteria. </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that under the proposed Special Authority criteria, approximately 5-6% of all thyroid cancer patients (equal to approximately 20 patients per year) would be eligible for lenvatinib treatment if it were funded, and noted that many of these patients would have likely received one or more courses of radioactive iodine. </p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that patients with radioactive iodine refractory differentiated thyroid cancer currently receive best supportive care and considered that this is appropriate comparator for lenvatinib in this indication. </p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that hypertension was a common adverse event associated with lenvatinib in the SELECT trial, and therefore considered that anti-hypertensives would likely be used concurrently in many patients.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that if lenvatinib were funded, there may be an increased need for imaging resources which would align with imaging requirements in the SELECT trial, however as an oral medication it was unlikely to have any other substantial impacts to health system resources. </p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered likely uptake in the first year could be 60%, rising in later years to 90-95%, reflective of the crossover uptake seen in the SELECT trial. The Subcommittee considered that the duration of response of 30 months demonstrated in the SELECT trial would indicate that patients may remain on treatment into a third year.</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that 95% of thyroid cancer is differentiated, of which approximately 5 to 10% of patients will develop metastatic disease, and 60 to 70% of these patients 5-10% patients will become radioiodine refractory (<a href=""https://www.karger.com/Article/Fulltext/502229"" target=""_blank"" style=""font-size: 12pt;""><b>Fugazzola et al. Eur Thyroid J. 2019;8:227–45</b></a>). </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that patients with thyroid cancer in New Zealand are relatively young, with approximately 75% of patients aged 25-64 years (<a href=""https://www.health.govt.nz/system/files/documents/publications/new-cancer-registrations-2017-dec19_0.xlsx"" target=""_blank"" style=""font-size: 12pt;""><b>New Zealand Cancer Registry. 2017</b></a>). The Subcommittee noted that females have a higher rate of thyroid cancer of 8.3 per 100,000, compared with 4.0 per 100,000 for males<b> </b>(<a href=""https://www.health.govt.nz/system/files/documents/publications/new-cancer-registrations-2017-dec19_0.xlsx"" target=""_blank"" style=""font-size: 12pt;""><b>New Zealand Cancer Registry. 2017</b></a>). </p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that Māori are disproportionately affected by thyroid cancer, with an age-standardised rate of thyroid cancer registration in 2015 of 8.6 per 100,000 for Māori compared with 5.4 per 100,000 for non-Māori, while mortality from thyroid cancer was 1.7 for Māori compared with 0.3 per 100,000 for non-Māori (Ministry of Health. 2020, <i>provided to supplier</i>). The Subcommittee also noted that Pacific people have previously been reported to have a higher age-standardised rate of thyroid cancer compared with European/other New Zealanders; standardised rate ratio 1.27 for Pacific males compared with European/other males (95% confidence interval (CI): 0.74-2.18) and 3.58 (2.87-4.47) for Pacific females compared with European/other females (<a href=""https://www.otago.ac.nz/wellington/otago036828.pdf"" target=""_blank"" style=""font-size: 12pt;""><b>Meredith et al. Canc Caus Contr. 2012;23:1173-84</b></a>). </p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>\xa0The Subcommittee noted the results of the randomised (2:1), double-blind, placebo-controlled phase III SELECT trial after the primary data cut-off in November 2013 (<a href=""https://pubmed.ncbi.nlm.nih.gov/25671254/"" target=""_blank"" style=""font-size: 12pt;""><b>Schlumberger et al. N Engl J Med. 2015;372:621-30</b></a>). The Subcommittee noted that 10-15% of trial participants had poorly differentiated thyroid cancer and that this patient group was not included as part of this application. The Subcommittee noted that the median progression-free survival was 18.3 months in the lenvatinib group compared with 3.6 months in placebo; hazard ratio (HR) for progression or death 0.21 (95% CI: 0.14-0.31; P&lt;0.001). The Subcommittee noted that the response rate was 64.8% in the lenvatinib group compared with 1.5% in the placebo group, odds ratio 28.9 (95% CI: 12.5-66.9; P&lt;0.001). </p><p>1.4.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that 95.6% of patients originally assigned to placebo crossed over to lenvatinib in the subsequent optional open-label extension phase of the trial. The Subcommittee noted that the crude overall survival was not statistically significant, and considered that this was likely due to the large amount of cross over; however, when adjusted to correct for potential cross-over effects (resampling with a bootstrapping method), the reported crossover-corrected hazard ratio was 0.62 (95% CI: 0.40- to 1.00, P=0.051; <a href=""https://www.nejm.org/doi/suppl/10.1056/NEJMoa1406470/suppl_file/nejmoa1406470_appendix.pdf"" target=""_blank"" style=""font-size: 12pt;""><b>Figure S4 in the Supplementary Appendix to Schlumberger et al. 2015</b></a>). </p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that NICE guidance published in <a href=""https://www.nice.org.uk/guidance/ta535/resources/lenvatinib-and-sorafenib-for-treating-differentiated-thyroid-cancer-after-radioactive-iodine-pdf-82606902620101"" target=""_blank"" style=""font-size: 12pt;""><b>August 2018</b></a><span style=""font-size: 12pt; font-family: Arial, sans-serif;""> regarding lenvatinib (and sorafenib) for treating differentiated thyroid cancer after radioactive iodine had reported that</span><span style=""background-color: rgb(250, 250, 251); color: black;""> “in SELECT, median overall survival for lenvatinib was 41.6\xa0months compared with 34.5\xa0</span><span style=""background-color: rgb(250, 250, 251); color: rgb(14, 14, 14);"">months for placebo. After correcting for crossover, there was a statistically significant overall survival benefit for lenvatinib compared with placebo (RPSFT-adjusted HR 0.54, 95% bootstrapping CI 0.36 to 0.80)”, where RPSFT referred to the rank preserving structural failure time method. The Subcommittee noted that the supplier application had stated this was based on analysis of an August 2015 data cut-off </span>with median OS of 41.6 months for lenvatinib versus 19.1 months for placebo. The Subcommittee considered the statistical methodology to be appropriate and that the statistically adjusted crossover-corrected results appeared credible.\xa0</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the RECIST v1.1 response rate according to RECIST v1.1 in the lenvatinib group, from an updated analysis with data cut-off in September 2016, was 64.8% compared with 1.5% in the placebo group (odds ratio 28.87, 95% CI: 12.46-66.86, P&lt;0.001). The Subcommittee also noted that the median duration of response for all lenvatinib responders was 30 months, indicating lenvatinib responders having prolonged, durable and clinically meaningful responses (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958278/"" target=""_blank"" style=""font-size: 12pt;""><b>Gianoukakis et al. Endocr Relat Cancer. 2018;25:699-704</b></a>).</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that this single randomised controlled trial represented good quality evidence of moderate strength. </p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered the Special Authority proposed by the supplier was overall appropriate. The Subcommittee considered that the WHO performance status should be amended to the Eastern Cooperative Oncology Group (ECOG) performance status, noting that while the two measurements are very similar in practice, New Zealand clinicians are more familiar ECOG, and that this would also maintain consistency with other oncology Special Authority criteria. </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that under the proposed Special Authority criteria, approximately 5-6% of all thyroid cancer patients (equal to approximately 20 patients per year) would be eligible for lenvatinib treatment if it were funded, and noted that many of these patients would have likely received one or more courses of radioactive iodine. </p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that patients with radioactive iodine refractory differentiated thyroid cancer currently receive best supportive care and considered that this is appropriate comparator for lenvatinib in this indication. </p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that hypertension was a common adverse event associated with lenvatinib in the SELECT trial, and therefore considered that anti-hypertensives would likely be used concurrently in many patients.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that if lenvatinib were funded, there may be an increased need for imaging resources which would align with imaging requirements in the SELECT trial, however as an oral medication it was unlikely to have any other substantial impacts to health system resources. </p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered likely uptake in the first year could be 60%, rising in later years to 90-95%, reflective of the crossover uptake seen in the SELECT trial. The Subcommittee considered that the duration of response of 30 months demonstrated in the SELECT trial would indicate that patients may remain on treatment into a third year.</p>', 'change': None}, 'Published_Application': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed the application for lenvatinib for the treatment of progressive, locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed the application for lenvatinib for the treatment of progressive, locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.</p>', 'change': None}, 'PTAC_Comments': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In regards to items 6 and 7 and CaTSoP’s consideration of tyrosine kinase inhibitors e.g. sunitinib, pazopanib, lenvatinib:</p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the Subcommittee’s recommendations, and also that it had suggested a broader review of the RCC treatment landscape in New Zealand and internationally, including with feedback from specialist groups such as the Genitourinary cancers special interest group.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In regards to items 6 and 7 and CaTSoP’s consideration of tyrosine kinase inhibitors e.g. sunitinib, pazopanib, lenvatinib:</p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the Subcommittee’s recommendations, and also that it had suggested a broader review of the RCC treatment landscape in New Zealand and internationally, including with feedback from specialist groups such as the Genitourinary cancers special interest group.\xa0</p>', 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2021', 'fs': 'Feb 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 16 October 2020.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 16 October 2020.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZFU42AP'}, 'Id': 'a0POZ00000EZFU42AP', 'Event_Date__c': '2021-02-25', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 16 October 2020.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'High', 'Formatted_Date__c': 'Feb 2021', 'Published_Recommendation__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that lenvatinib be listed for the treatment of radioactive iodine-refractory differentiated thyroid cancer with a <b>high priority</b> within the context of treatment of malignancy, subject to the following Special Authority criteria:</p><p><b style=""font-size: 9pt;"">Lenvatinib</b></p><p><b style=""font-size: 9pt;"">INITIAL APPLICATION</b><span style=""font-size: 9pt;""> – (thyroid cancer) Applications only from a relevant specialist or any other medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1 \xa0\xa0\xa0\xa0The patient has locally advanced or metastatic differentiated thyroid cancer; and</span></p><p><span style=""font-size: 9pt;"">2 \xa0\xa0\xa0\xa0The patient has radiologically determined progressive disease; and</span></p><p><span style=""font-size: 9pt;"">3 \xa0\xa0\xa0\xa0The patient must be radioactive iodine (RAI) refractory, defined as:</span></p><p><span style=""font-size: 9pt;"">3.1\xa0\xa0A lesion without iodine uptake in a RAI scan; or</span></p><p><span style=""font-size: 9pt;"">3.2 \xa0\xa0Receiving cumulative RAI &gt;600 mCi; or</span></p><p><span style=""font-size: 9pt;"">3.3 \xa0\xa0Experiencing progression after a RAI treatment within 12 months; or</span></p><p><span style=""font-size: 9pt;"">3.4\xa0\xa0Experiencing progression after two RAI treatments administered within 12 months of each other; and</span></p><p><span style=""font-size: 9pt;"">4 \xa0\xa0\xa0\xa0\xa0The patient must have thyroid stimulating hormone (TSH) adequately repressed; and</span></p><p><span style=""font-size: 9pt;"">5 \xa0\xa0\xa0\xa0\xa0The patient must not be a candidate for radiotherapy with curative intent; and </span></p><p><span style=""font-size: 9pt;"">6 \xa0\xa0\xa0\xa0\xa0Surgery is inappropriate; and</span></p><p><span style=""font-size: 9pt;"">7 \xa0\xa0\xa0\xa0\xa0The patient must have a ECOG performance status of 0-1.</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p><b style=""font-size: 9pt;"">RENEWAL</b><span style=""font-size: 9pt;""> – (thyroid cancer) Applications only from a relevant specialist or any other medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1 \xa0\xa0\xa0No evidence of disease progression; and</span></p><p><span style=""font-size: 9pt;"">2 \xa0\xa0\xa0The treatment remains appropriate and the patient is benefiting from treatment.</span></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>In making this recommendation, the Subcommittee considered the high clinical need of patients with radioactive iodine-refractory differentiated thyroid cancer, the disproportionate rate of thyroid cancer in Māori and Pacific peoples, and the moderate strength, good quality evidence of the benefit of lenvatinib in this patient population.</p>', 'Published_Application__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed the application for lenvatinib for the treatment of progressive, locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.</p>', 'Published_Discussion__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that 95% of thyroid cancer is differentiated, of which approximately 5 to 10% of patients will develop metastatic disease, and 60 to 70% of these patients 5-10% patients will become radioiodine refractory (<a href=""https://www.karger.com/Article/Fulltext/502229"" target=""_blank"" style=""font-size: 12pt;""><b>Fugazzola et al. Eur Thyroid J. 2019;8:227–45</b></a>). </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that patients with thyroid cancer in New Zealand are relatively young, with approximately 75% of patients aged 25-64 years (<a href=""https://www.health.govt.nz/system/files/documents/publications/new-cancer-registrations-2017-dec19_0.xlsx"" target=""_blank"" style=""font-size: 12pt;""><b>New Zealand Cancer Registry. 2017</b></a>). The Subcommittee noted that females have a higher rate of thyroid cancer of 8.3 per 100,000, compared with 4.0 per 100,000 for males<b> </b>(<a href=""https://www.health.govt.nz/system/files/documents/publications/new-cancer-registrations-2017-dec19_0.xlsx"" target=""_blank"" style=""font-size: 12pt;""><b>New Zealand Cancer Registry. 2017</b></a>). </p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that Māori are disproportionately affected by thyroid cancer, with an age-standardised rate of thyroid cancer registration in 2015 of 8.6 per 100,000 for Māori compared with 5.4 per 100,000 for non-Māori, while mortality from thyroid cancer was 1.7 for Māori compared with 0.3 per 100,000 for non-Māori (Ministry of Health. 2020, <i>provided to supplier</i>). The Subcommittee also noted that Pacific people have previously been reported to have a higher age-standardised rate of thyroid cancer compared with European/other New Zealanders; standardised rate ratio 1.27 for Pacific males compared with European/other males (95% confidence interval (CI): 0.74-2.18) and 3.58 (2.87-4.47) for Pacific females compared with European/other females (<a href=""https://www.otago.ac.nz/wellington/otago036828.pdf"" target=""_blank"" style=""font-size: 12pt;""><b>Meredith et al. Canc Caus Contr. 2012;23:1173-84</b></a>). </p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>\xa0The Subcommittee noted the results of the randomised (2:1), double-blind, placebo-controlled phase III SELECT trial after the primary data cut-off in November 2013 (<a href=""https://pubmed.ncbi.nlm.nih.gov/25671254/"" target=""_blank"" style=""font-size: 12pt;""><b>Schlumberger et al. N Engl J Med. 2015;372:621-30</b></a>). The Subcommittee noted that 10-15% of trial participants had poorly differentiated thyroid cancer and that this patient group was not included as part of this application. The Subcommittee noted that the median progression-free survival was 18.3 months in the lenvatinib group compared with 3.6 months in placebo; hazard ratio (HR) for progression or death 0.21 (95% CI: 0.14-0.31; P&lt;0.001). The Subcommittee noted that the response rate was 64.8% in the lenvatinib group compared with 1.5% in the placebo group, odds ratio 28.9 (95% CI: 12.5-66.9; P&lt;0.001). </p><p>1.4.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that 95.6% of patients originally assigned to placebo crossed over to lenvatinib in the subsequent optional open-label extension phase of the trial. The Subcommittee noted that the crude overall survival was not statistically significant, and considered that this was likely due to the large amount of cross over; however, when adjusted to correct for potential cross-over effects (resampling with a bootstrapping method), the reported crossover-corrected hazard ratio was 0.62 (95% CI: 0.40- to 1.00, P=0.051; <a href=""https://www.nejm.org/doi/suppl/10.1056/NEJMoa1406470/suppl_file/nejmoa1406470_appendix.pdf"" target=""_blank"" style=""font-size: 12pt;""><b>Figure S4 in the Supplementary Appendix to Schlumberger et al. 2015</b></a>). </p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0</span>The Subcommittee noted that NICE guidance published in <a href=""https://www.nice.org.uk/guidance/ta535/resources/lenvatinib-and-sorafenib-for-treating-differentiated-thyroid-cancer-after-radioactive-iodine-pdf-82606902620101"" target=""_blank"" style=""font-size: 12pt;""><b>August 2018</b></a><span style=""font-size: 12pt; font-family: Arial, sans-serif;""> regarding lenvatinib (and sorafenib) for treating differentiated thyroid cancer after radioactive iodine had reported that</span><span style=""background-color: rgb(250, 250, 251); color: black;""> “in SELECT, median overall survival for lenvatinib was 41.6\xa0months compared with 34.5\xa0</span><span style=""background-color: rgb(250, 250, 251); color: rgb(14, 14, 14);"">months for placebo. After correcting for crossover, there was a statistically significant overall survival benefit for lenvatinib compared with placebo (RPSFT-adjusted HR 0.54, 95% bootstrapping CI 0.36 to 0.80)”, where RPSFT referred to the rank preserving structural failure time method. The Subcommittee noted that the supplier application had stated this was based on analysis of an August 2015 data cut-off </span>with median OS of 41.6 months for lenvatinib versus 19.1 months for placebo. The Subcommittee considered the statistical methodology to be appropriate and that the statistically adjusted crossover-corrected results appeared credible.\xa0</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the RECIST v1.1 response rate according to RECIST v1.1 in the lenvatinib group, from an updated analysis with data cut-off in September 2016, was 64.8% compared with 1.5% in the placebo group (odds ratio 28.87, 95% CI: 12.46-66.86, P&lt;0.001). The Subcommittee also noted that the median duration of response for all lenvatinib responders was 30 months, indicating lenvatinib responders having prolonged, durable and clinically meaningful responses (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958278/"" target=""_blank"" style=""font-size: 12pt;""><b>Gianoukakis et al. Endocr Relat Cancer. 2018;25:699-704</b></a>).</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that this single randomised controlled trial represented good quality evidence of moderate strength. </p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered the Special Authority proposed by the supplier was overall appropriate. The Subcommittee considered that the WHO performance status should be amended to the Eastern Cooperative Oncology Group (ECOG) performance status, noting that while the two measurements are very similar in practice, New Zealand clinicians are more familiar ECOG, and that this would also maintain consistency with other oncology Special Authority criteria. </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that under the proposed Special Authority criteria, approximately 5-6% of all thyroid cancer patients (equal to approximately 20 patients per year) would be eligible for lenvatinib treatment if it were funded, and noted that many of these patients would have likely received one or more courses of radioactive iodine. </p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that patients with radioactive iodine refractory differentiated thyroid cancer currently receive best supportive care and considered that this is appropriate comparator for lenvatinib in this indication. </p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that hypertension was a common adverse event associated with lenvatinib in the SELECT trial, and therefore considered that anti-hypertensives would likely be used concurrently in many patients.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that if lenvatinib were funded, there may be an increased need for imaging resources which would align with imaging requirements in the SELECT trial, however as an oral medication it was unlikely to have any other substantial impacts to health system resources. </p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered likely uptake in the first year could be 60%, rising in later years to 90-95%, reflective of the crossover uptake seen in the SELECT trial. The Subcommittee considered that the duration of response of 30 months demonstrated in the SELECT trial would indicate that patients may remain on treatment into a third year.</p>', 'PTAC_Comments__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In regards to items 6 and 7 and CaTSoP’s consideration of tyrosine kinase inhibitors e.g. sunitinib, pazopanib, lenvatinib:</p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the Subcommittee’s recommendations, and also that it had suggested a broader review of the RCC treatment landscape in New Zealand and internationally, including with feedback from specialist groups such as the Genitourinary cancers special interest group.\xa0</p>', 'Status_History__c': 'a132P000000CdHHQA0'}, 'change': None}]",Jul 2020,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2021', 'fs': 'Mar 2021', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZFU52AP'}, 'Id': 'a0POZ00000EZFU52AP', 'Event_Date__c': '2021-03-28', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Mar 2021', 'Status_History__c': 'a132P000000CifWQAS'}, 'change': None}]",Mar 2021,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2021', 'fs': 'Oct 2021', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZFU62AP'}, 'Id': 'a0POZ00000EZFU62AP', 'Event_Date__c': '2021-10-26', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Oct 2021', 'Status_History__c': 'a132P000000DGwBQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2023', 'fs': 'Mar 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZFU72AP'}, 'Id': 'a0POZ00000EZFU72AP', 'Event_Date__c': '2023-03-09', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Mar 2023', 'Status_History__c': 'a132P000000EDT6QAO'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2023', 'fs': 'Sep 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZFU82AP'}, 'Id': 'a0POZ00000EZFU82AP', 'Event_Date__c': '2023-09-08', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Sep 2023', 'Status_History__c': 'a13OZ000001vnusYAA'}, 'change': None}]",Oct 2021,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2024-09-lenvatinib-consultation"" target=""_blank"">Consultation notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2024-09-lenvatinib-consultation"" target=""_blank"">Consultation notification</a></p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2024', 'fs': 'Sep 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZFU92AP'}, 'Id': 'a0POZ00000EZFU92AP', 'Event_Date__c': '2024-09-18', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Summary__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2024-09-lenvatinib-consultation"" target=""_blank"">Consultation notification</a></p>', 'Formatted_Date__c': 'Sep 2024', 'Status_History__c': 'a13OZ00000EMN62YAH'}, 'change': None}]",Sep 2024,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2024', 'fs': 'Oct 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZFUA2A5'}, 'Id': 'a0POZ00000EZFUA2A5', 'Event_Date__c': '2024-10-04', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Oct 2024', 'Status_History__c': 'a13OZ00000Ez37PYAR'}, 'change': None}]",Oct 2024,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/f-decision-to-fund-lenvatinib-for-thyroid-liver-and-kidney-cancers"" target=""_blank"">Notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/f-decision-to-fund-lenvatinib-for-thyroid-liver-and-kidney-cancers"" target=""_blank"">Notification</a></p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2024', 'fs': 'Nov 2024', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZFUB2A5'}, 'Id': 'a0POZ00000EZFUB2A5', 'Event_Date__c': '2024-11-06', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Summary__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/f-decision-to-fund-lenvatinib-for-thyroid-liver-and-kidney-cancers"" target=""_blank"">Notification</a></p>', 'Formatted_Date__c': 'Nov 2024', 'Status_History__c': 'a13OZ00000GGczRYAT'}, 'change': None}]",Nov 2024,False,True
